Prostate Cancer Clinical Trials in New York

Showing 121-140 of 223 trials

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

NCT00199849

To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.

Prostate CancerBladder CancerNon-small Cell Lung Cancer+2 more

Ludwig Institute for Cancer Research18 participantsStarted Sep 2004

New York, New York, United States • Houston, Texas, United States

COMPLETED< 1 mile

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

NCT05447637

This registry is for men who have prostate cancer and have had multigene panel hereditary testing. The registry will gather data on genetic testing results and how that information may change physician treatment or follow up recommendations. It will also gather data on the patient's experience with genetic testing, through a post-test survey to be completed 60-90days after results have been received and discussed with their provider.

Prostate Cancer

Invitae Corporation1,000 participantsStarted Nov 2019

San Diego, California, United States • San Francisco, California, United States • San Francisco, California, United States +16 more locations

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

Prostate Cancer Trials in Other Cities

Men Undergoing Radical Prostatectomy

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

A Survivorship Care Plan and Embedded Navigation Tool

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Radiation Therapy in Treating Patients With Prostate Cancer

Safety Study of MGA271 in Refractory Cancer

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Other Conditions in New York